Royalty Pharma plc
60.59USD
+0.0000 (+0.00%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.2B | 2.4B | 2.3B | 2.4B | 3.5B | 3.8B |
| Q1 | 562.0M | 684.0M | 568.0M | 568.2M | 630.6M | — |
| Q2 | 536.0M | 538.2M | 537.3M | 578.7M | 674.1M | — |
| Q3 | 573.5M | 536.3M | 564.7M | 609.3M | 884.8M | — |
| Q4 | 565.7M* | 596.1M* | 593.6M* | 622.0M* | 941.3M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .100 | 2.53 | 1.91 | 1.78 | 5.34 | 5.73 |
| Q1 | .120 | .760 | .010 | .550 | .670 | — |
| Q2 | .700 | .500 | .230 | .070 | .040 | — |
| Q3 | .320 | .160 | 1.21 | .670 | 1.18 | — |
| Q4 | -1.04* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .820* |
| .350* |
| .379* |
| 1.55 |
| — |